CANVAS study presented at ADA 2017 highlights heart and kidney protection for type 2 diabetes drug Invokana, and questions persist over an increased risk of amputations Continue Reading »
You can help more people with diabetes
The latest research in type 1 diabetes, type 2 diabetes, prediabetes, and beyond. Here you’ll find information on experimental therapies, new data and results, and scientific findings.
CANVAS study presented at ADA 2017 highlights heart and kidney protection for type 2 diabetes drug Invokana, and questions persist over an increased risk of amputations Continue Reading »
The latest evidence on Saxenda shows that three years of treatment with the drug lowers risk for type 2 diabetes by an impressive 79% Continue Reading »
Studies highlight reduced hypoglycemia risk for people with type 2 diabetes who switch to “next-gen” basal insulins Toujeo or Tresiba Continue Reading »
CVD-REAL study showed SGLT-2 inhibitors reduce the risk of hospitalization for heart failure in over 300,000 people with type 2 diabetes Continue Reading »
No fingersticks needed? Plus, a look at the “thinnest CGM ever” from Dexcom and Verily Continue Reading »
less risk of diabetes complications, lower A1c, improved weight loss and hypoglycemia; led by Novo Nordisk’s Victoza and semaglutide Continue Reading »
AADE’s Dr. Susan Guzman and diaTribe’s Adam Brown discuss how common stigma is, why it matters, and tips to overcome it Continue Reading »
Significant Improvement in A1c and time-in-range when adding CGM. Continue Reading »